What insurance policy changes affect code D56.5?

There are 3 tracked policy changes affecting code D56.5, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code D56.5?

Payers that have issued tracked updates for code D56.5 include: Aetna.

How do I get notified when code D56.5 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code D56.5. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code D56.5?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

D56.5 Insurance Policy Changes

ICD-10 D56.5 is officially defined as "Hemoglobin E-beta thalassemia." code D56.5 is referenced in 3 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code D56.5 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 4, 2026Medium impact
Hematopoietic Cell Transplantation for Thalassemia Major and Sickle Cell Anemia (CPB 0626, reviewed 2026-09-18)
Aetna's Clinical Policy Bulletin 0626 considers allogeneic hematopoietic cell transplantation medically necessary for thalassemia major and sickle cell anemia in children or young adults when the member meets the transplanting institution's written eligibility criteria. Where no such criteria exist, Aetna considers it medically necessary for thalassemia major in children or young adults with a haploidentical or HLA-matched donor, and for sickle cell anemia when the member has a haploidentical or HLA-matched donor and either a history of stroke or an increased risk of stroke or end-organ damage. Autologous transplant for thalassemia major or sickle cell anemia in children or young adults, treosulfan-based T-cell depleted haploidentical transplant for sickle cell disease or transfusion-dependent thalassemia, and use of T-lymphocyte subsets at engraftment to predict acute graft-versus-host disease risk are considered experimental, investigational or unproven.
Aetna · Identified Aug 17, 2026Medium impact
Hematopoietic Cell Transplantation for Thalassemia Major and Sickle Cell Anemia (CPB 0626, reviewed 2025-09-25)
Aetna's Clinical Policy Bulletin 0626 covers allogeneic hematopoietic cell transplantation (HCT) for thalassemia major and sickle cell anemia. Aetna considers allogeneic HCT medically necessary for thalassemia major in children or young adults (to age 45 years) when the member meets the transplanting institution's written eligibility criteria, and in the absence of such criteria when a haploidentical or HLA-matched donor is used. For sickle cell anemia in children or young adults, allogeneic HCT is medically necessary when the member meets the transplanting institution's written eligibility criteria, and in the absence of such criteria when the member has a haploidentical or HLA-matched donor and either a history of stroke or an increased risk of stroke or end-organ damage. Autologous HCT for these conditions, treosulfan-based T-cell depleted haplo-identical stem cell transplantation for sickle cell disease or transfusion-dependent thalassemia, and use of T-lymphocyte subsets at engraftment to predict the risk of acute graft-versus-host disease in thalassemia major are considered experimental, investigational, or unproven.
Aetna · Identified Aug 16, 2026Medium impact
Luspatercept-aamt (Reblozyl) (CPB 0963, reviewed 2026-06-12)
Aetna's commercial medical plans cover luspatercept-aamt (Reblozyl) as medically necessary for anemia with beta thalassemia and for anemia of myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm, when the criteria in the policy are met, and precertification is required. Aetna considers all other indications experimental, investigational, or unproven, and considers continuation of therapy medically necessary when the member has achieved or maintained a reduction in red blood cell transfusion burden and has not experienced an unacceptable toxicity from Reblozyl.

Watch D56.5

Get one email when a payer policy names D56.5, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Hematopoietic Cell Transplantation for Thalassemia Major and Sickle Cell Anemia (CPB 0626, reviewed 2026-09-18)

Hematopoietic Cell Transplantation for Thalassemia Major and Sickle Cell Anemia (CPB 0626, reviewed 2025-09-25)

Luspatercept-aamt (Reblozyl) (CPB 0963, reviewed 2026-06-12)

What insurance policy changes affect code D56.5?

Which payers have updated policy for code D56.5?

How do I get notified when code D56.5 policy changes?

Why do payers change policies for code D56.5?